Emilio Yángüez

8PUBLICATIONS
96CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 16, 2026
T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma.

|Jun 12, 2026
Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control.

|May 28, 2026
FAP-CD40 and PD1-IL2v combination therapy reprograms immunologically cold tumors through de novo intratumoral T cell-dendritic cell clusters.

|Apr 15, 2026
Precision modeling of tumor antigen-specific T-cell responses in humanized mice for preclinical assessment of cancer immunotherapies.

|Apr 07, 2026
A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.

Elena Garralda, Christoph Markert, Victor Moreno

|Jan 22, 2026
Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma.

Stephan Schmeing, Sina Nassiri, Gabrielle Leclercq-Cohen

Pageof 2

Frequent Collaborators

7 joint publications

Tamara Hüsser

4 joint publications

Marina Bacac

4 joint publications

Sylvia Herter

3 joint publications

Christian Klein